Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 28, 2020

P&G Health’s nasal gel tech shows potential against Covid-19

A study conducted by P&G Health, the healthcare division of The Procter & Gamble Company, has found that its nasal mucoadhesive gel technology could reduce SARS-CoV-2 coronavirus infection of cells.

A study conducted by P&G Health, the healthcare division of The Procter & Gamble Company, has found that its nasal mucoadhesive gel technology could reduce SARS-CoV-2 coronavirus infection of cells.

The company’s nasal mucoadhesive gel technology works as an intranasal spray. It was originally intended for use against common cold viruses.

A standard antiviral laboratory test was carried out by the research team at the P&G Health to assess the technology’s ability to prevent the SARS-CoV-2 virus from infecting cells it needs for replication.

During the test, the nasal mucoadhesive gel formulation was combined with the virus for one, five, and ten minutes. These mixtures were added to cell monolayers and virus quantity was then assessed from the cells after a seven-day incubation.

It was found that the nasal mucoadhesive gel reduced the level of SARS-CoV-2 viruses by 99.5% at one-minute exposure. The test showed greater reductions with five and ten minutes of exposure.

According to the company, this suggests the nasal mucoadhesive gel may reduce SARS-CoV-2 virus infection of cells.

Content from our partners
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

However, it noted that further clinical research is required to confirm whether the technology can offer a protective benefit against SARS-CoV-2 in humans.

P&G Health is currently evaluating a number of research proposals to evaluate the efficacy of the nasal mucoadhesive gel against a number of respiratory viruses, including SARS-CoV-2.

The nasal mucoadhesive gel is currently used in Vicks First Defence intranasal spray, which is a medical device in Europe approved for use against common cold viruses.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU